Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Genesis Acquires 100% Of Biostore NZ Ltd

Genesis Acquires 100% Of Biostore NZ Ltd And First Commercial Licensing Agreement For Biostore™ Is Signed

Auckland, 15 August 2001 - New Zealand biotechnology company, Genesis Research and Development Corporation (NZSE/ASX: GEN), today announced that it had acquired the remaining 23.7% interest in its subsidiary, BioStore NZ Limited, at independent valuation.

“The existing capital structure of BioStore could not adequately support our commercialisation plans,” says Genesis Chief Executive, Dr Jim Watson. “By acquiring the minority interest, Genesis can now provide the support required for the development and commercialisation of BioStore™ products.”

Genesis will issue approximately 230,000 shares and make a small cash payment to the vendors.

BioStore™ is a patented preservation technology which physically induces dormancy in cellular products. This allows cells to be stored at 4ºC or frozen and later thawed without deterioration. Alternatively, BioStore™ treated cells can be freeze-dried, stored without refrigeration, and later reconstituted. This provides new storage and distribution opportunities and can reduce the costs of traditional storage technologies.

BioStore has also licensed its technology to Australian veterinary pharmaceuticals and animal health products manufacturer, Jurox Pty Ltd.

The agreement, which represents the first commercial application of BioStore™, enables Jurox to freeze-dry nucleated cellular products stored in a BioStore™ solution, and later revive them in a novel veterinary application.

As a result of this agreement BioStore will realise royalty income based on Jurox’s commercial success. Meanwhile Jurox is exploring further potential veterinary applications for BioStore™.

“BioStore’s unique preservation technology makes possible a whole new class of product formulations and treatment delivery systems for veterinary applications,” says Jurox CEO, John O’Brien. “We believe we have the potential to open up a range of veterinary opportunities for BioStore.”

Investing in BioStore
As it moves to commercialise the technology Genesis has considerably strengthened its BioStore team. It has contracted Dr Earl Stevens to manage the development of commercial applications. With a PhD in Biochemistry, a background in general management, mergers and commercial development, Dr Stevens is tasked with identifying, prioritising and speeding up the development of BioStore opportunities with strong commercial potential.

“The future commercialisation of BioStore’s patented technologies will be via agreements such as this,” says Dr Stevens. “Our primary focus for the near term will be on blood product applications, including platelet and red blood cell storage, where our ability to store platelets for 21 days at 4° C represents a significant advantage over other storage technologies.”

Genesis has also appointed a Chief Scientist for BioStore, Dr Anthony Matthews. A New Zealander and graduate of the University of Auckland, Dr Matthews has worked extensively in North America, at Rice University in Texas and Baxter Haemoglobin in Colorado. He is a biochemist with a background in physical chemistry, has worked with a wide range of tissues and holds a number of recombinant haemoglobin and protein purification related patents. Genesis has also appointed Dr Helen Cao to the BioStore team. She holds a Bachelor’s degree in medicine and a Masters in microbiology and immunology from Nanjing Medical University, and has recently completed a Masters in health sciences and a PhD at Auckland University.


About Genesis
Founded in 1994, Genesis is a New Zealand-based biotechnology company committed to the building of a strong genomic platform for the development of innovative products in human health and agriculture. Genesis partners with industry leaders to develop products that have global market potential through the mining of its extensive microbe, plant and mammalian EST databases. Genesis has three programs in human clinical development, with additional programs in pre-clinical development and in plant biotechnology. Genesis now owns 100 percent of the shares in BioStore NZ Ltd, which in turn owns all the patents to BioStore™ preservation solutions. For more information, please visit

# # #

© Scoop Media

Business Headlines | Sci-Tech Headlines


Infrastructure Commission: Te Waihanga Releases Report On Water Infrastructure

The New Zealand Infrastructure Commission, Te Waihanga’s latest discussion document highlights the importance of current reforms in the water sector. Its State of Play discussion document about water infrastructure is one of a series looking at the ... More>>

Sci-Tech: Perseverance Rover Lands On Mars – Expert Reaction

NASA has landed a car-sized rover on the red planet to search for signs of past life. The vehicle has more instruments than the four rovers preceding it, and it’s also carrying gear that could help pave the way for human exploration of Mars. The ... More>>


ASB: Quarterly Economic Forecast Predicts OCR Hike As Early As August 2022

Predictions of interest rate rises have been brought forward 12 months in ASB’s latest Quarterly Economic Forecast. Chief Economist Nick Tuffley now expects the RBNZ to begin raising the OCR from its current level of 0.25% as early as August ... More>>

Real Estate: House Price Growth Rates In Hawke’s Bay Skyrocket Ahead Of Rest Of New Zealand

Hawke’s Bay is leading the property ‘pack’ proving a post lockdown land of milk and money, continuing to outstrip the rest of the country with the highest annual growth rate in house price values. But experts warn an overheated market is fast ... More>>

ACT: Matariki Almost A Half Billion Dollar Tax On Business

“Official advice to the Government says an extra public holiday at Matariki could cost almost $450 million,” ACT Leader David Seymour can reveal. “This is a perfect example of the Prime Minister doing what’s popular versus what’s responsible. ... More>>

Genesis: Assessing 6,000 GWh Of Renewable Generation Options For Development By 2025

Genesis is assessing 6,000 GWh of renewable generation options for development after starting a closed RFP process with 11 partners. Those invited to participate offer a range of technologies as Genesis continues to execute its Future-gen strategy to ... More>>

OECD: Unemployment Rate Stable At 6.9% In December 2020, 1.7 Percentage Points Higher Than In February 2020

The OECD area unemployment rate was stable at 6.9% in December 2020, remaining 1.7 percentage points above the level observed in February 2020, before the COVID-19 pandemic hit the labour market. [1] In December, the unemployment rate was also stable ... More>>

Stats NZ: Unemployment Drops To 4.9 Percent As Employment Picks Up

The seasonally adjusted unemployment rate dropped to 4.9 percent in the December 2020 quarter, from 5.3 percent in the September 2020 quarter, Stats NZ said today. Last quarter’s unemployment rate of 5.3 percent followed the largest increase observed ... More>>